Boca Raton, Florida
The two-day NobleCON13 annual small-cap and emerging growth investor conference provides a forum where private and publicly traded emerging growth companies with less than $2 billion in market capitalization can connect with the investment community, fund managers, and high net worth investors who focus on small cap equities. The 2017 Conference will include presentations by CEOs and CFOs, expert panels moderated by industry leaders, and the opportunity for investors to meet and network with management of presenting companies on a one-on-one basis. NobleCon13 also provides networking opportunities through social activities and special events. For more information visit NobleConference.com
Naked Brand (NAKD)
Naked Brand (NASDAQ: NAKD) designs, manufactures and sells men's and women's underwear, intimate apparel, loungewear and sleepwear products in the United States and Canada. It offers various innerwear products for men, including boxer briefs, trunks, briefs, undershirts, T-shirts, lounge pants, lounge shorts and robes, as well as loungewear and sleepwear products for women, such as boyshorts, hipsters, lounge pants and tops, camisoles, tank tops, pajamas, chemises, sleepshirts and robes primarily under the Naked brand name. The company sells its products to consumers and retailers through wholesale channels and direct-to-consumer channels. For more information, visit the company's website at www.thenakedshop.com.
Safeguard Scientifics (SFE)
Safeguard Scientifics (NYSE: SFE) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. The company targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the internet of everything, enhanced security and predictive analytics. Safeguard Scientifics typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. It has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. For more information, visit the company's website at www.safeguard.com.
Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals (NASDAQ: TNXP) is a clinical-stage pharmaceutical company that develops medicines for common disorders of the central nervous system. The company's lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, a phase III clinical stage for the treatment of PTSD; and phase II clinical stage for the treatment of military-related PTSD. For more information, visit the company's website www.tonixpharma.com.
Computer Task Group (CTG)
Computer Task Group (NASDAQ: CTG) is an information technology (IT) solutions and staffing services company in North America and Europe. The company's solutions include the implementation and optimization of packaged software applications; development and deployment of customized software and solutions designed to fit the needs of a specific client or market; and design and distribution of complex technology components. The company's IT and other staffing solutions include recruiting, retaining, and managing IT and other talent primarily for technology service providers and companies with multiple locations. It also provides IT services for the healthcare provider market that include clinical systems integration and implementation, application management, technology support for medical imaging, training and technical resources. For more information, visit the company's website at www.ctg.com.
The E. W. Scripps Company (SSP)
The E. W. Scripps Company (NYSE: SSP) operates as a media enterprise with a portfolio of television, radio and digital media brands. The company produces news, information and entertainment content and operates local digital sites offering local news, information, and user-generated content, as well as national content and other content sources. It is also involved in the national digital businesses, such as Newsy, an over-the-top video news service; and Midroll, a podcast industry that creates original podcasts and operates a network. In addition, the company provides television programming services, and syndication services for news features and comics for the newspaper industry. For more information, visit the company's website at www.scripps.com.
Heat Biologics (HTBX)
Heat Biologics (NASDAQ: HTBX) is a biopharmaceutical company focused on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy. For more information, visit the company's website at www.heatbio.com.
Information Services Group (III)
Information Services Group (NASDAQ: III) provides technology insights, market intelligence, and advisory services in the Americas, Europe and the Asia Pacific. The company supports private and public sector organizations to transform and optimize operational environments through research, benchmarking, consulting and managed services with a focus on information technology, business process transformation, program management services, and enterprise resource planning. The company serves private sector clients operating in the financial services, telecommunications, healthcare and pharmaceuticals, manufacturing, transportation and travel, and energy and utilities industries; and public sector customers. For more information, visit the company's website at www.isg-one.com.
Delcath Systems (DCTH)
Delcath Systems (NASDAQ: DCTH) operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. For more information, visit the company's website at www.delcath.com.
KEYW Holding (KEYW)
KEYW Holding (NASDAQ: KEYW) provides mission-critical cybersecurity, cyber superiority, and geospatial intelligence solutions in the United States. It operates in two segments, Government Solutions and Commercial Cyber Solutions. The company offers solutions, services and products to support the intelligence process, including the collection, processing, analysis and dissemination of intelligence information in the domains of cyberspace and geospace, as well as the protection of networks and related infrastructure. For more information, visit the company's website at www.keywcorp.com.
Agile Therapeutics (AGRX)
Agile Therapeutics (NASDAQ: AGRX) is a specialty pharmaceutical company that focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate, Twirla, is a once-weekly contraceptive patch currently in phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. For more information, visit the company's website at www.agiletherapeutics.com.
Entravision Communications (EVC)
Entravision Communications (NYSE: EVC) operates as a media company targeting and engaging Hispanics across media channels and advertising platforms in the United States and certain border markets of Mexico. The company operates through three segments: Television Broadcasting, Radio Broadcasting, and Digital Media. Entravision owns and operates television stations that broadcast drama shows, talk shows, novelas, entertainment magazines, news magazines, national news, specials, late news, children's programs, sports, reality, comedy shows and movies; as well as owns and operates radio stations that broadcast advertising, news, traffic, weather, promotions and community events. In addition, it operates a proprietary technology and data platform that delivers digital advertising solutions in various advertising formats. For more information, visit the company's website at www.entravision.com.
Kratos Defense & Security Solutions (KTOS)
Kratos Defense & Security Solutions (NASDAQ: KTOS) provides mission critical products, solutions and services primarily for the government and commercial customers. The company operates through three segments: Kratos Government Solutions, Unmanned Systems, and Public Safety & Security. The Kratos Government Solutions segment offers microwave electronic products; satellite communications; technical and training solutions; modular systems; and defense and rocket support services. The Unmanned Systems segment provides unmanned aerial, ground, seaborne and command, control and communications systems. For more information, visit the company's website at www.kratosdefense.com.
OncoSec Medical (ONCS)
OncoSec Medical (NASDAQ: ONCS) designs, develops and commercializes gene therapies, therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company's therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor. For more information, visit the company's website at www.oncosec.com.
Synthesis Energy Systems (SYMX)
Synthesis Energy Systems (NASDAQ: SYMX) is an energy and gasification technology company that, together with its subsidiaries, provides proprietary gasification technology systems and solutions to the energy and chemical industries worldwide. The company offers U-GAS fluidized bed gasification technology that produces synthesis gas from various energy resources, including coal, biomass, municipal wastes, refuse derived fuels, and petroleum coke. Its synthesis gas can be converted into a range of energy and chemical products such as industrial fuel gas, substitute natural gas, electricity, hydrogen, ammonia and methanol. The company also has rights to sublicense U-GAS systems to third parties for coal, and coal and biomass mixtures, as well as for biomass projects. In addition, it offers XL3000 gasification system for use in synthesis gas projects, such as electricity, steelmaking, industrial chemicals, fertilizers, substitute natural gas, and transportation fuels. For more information, visit the company's website www.synthesisenergy.com.
Bionik Laboratories (BNKL)
Bionik Laboratories (OTC: BNKL) is a medical device and robotics company focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders. It specializes in designing, developing and commercializing physical rehabilitation technologies, prosthetics and assisted robotic products. The company offers InMotion Systems, which include the InMotion ARM that allows clinicians to deliver sensormotor therapy to the shoulder and elbow to develop new neural pathways; InMotion Hand, an add-on module to be used with the InMotion ARM; InMotion WRIST, which enables clinicians to deliver optimum intensive sensorimotor wrist and forearm therapy to patients with neurological conditions; and InMotion ANKLE, a lower body robotic exoskeletal system. For more information, visit the company's website at www.bioniklabs.com.
Excel Corporation (EXCC)
Excel Corporation (OTC: EXCC) provides integrated financial and transaction processing services to small and medium-sized businesses in the United States. The company provides an integrated suite of third-party merchant payment processing services and related proprietary software enabling products that deliver credit and debit card-based Internet payments processing solutions to small and mid-sized merchants operating in physical business environments, on the internet, and in retail settings requiring wired and wireless mobile payment solutions. For more information, visit the company's website at www.excelcorpusa.com.
Interpace Diagnostics Group (IDXG)
Interpace Diagnostics Group (NASDAQ: IDXG) develops and commercializes molecular diagnostic tests for physicians and patients to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers in the United States. The company offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; ThyGenX, a sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules; ThyraMIR, a novel microRNA gene expression classifier; and PathFinder TG Barrett's, an esophageal cancer risk classifier. For more information, visit the company's website at www.pdi-inc.com.
Del Mar Pharmaceuticals (DMPI)
Del Mar Pharmaceuticals (NASDAQ: DMPI) is a pharmaceutical company that develops and commercializes new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients. For more information, visit the company's website at www.delmarpharma.com.
Marlin Gold Mining (MLNGF)
Marlin Gold Mining (OTC: MLNGF) explores for, develops, and produces gold in the Americas. The company also explores for silver ores. It principal project is the Taunus deposit that is held by the La Trinidad property located in Sinaloa, Mexico. The company was formerly known as Oro Mining Ltd. and changed its name to Marlin Gold Mining Ltd. in November 2012. Marlin Gold Mining Ltd. was incorporated in 2000 and is headquartered in Vancouver, Canada. For more information, visit the company's website at www.marlingold.com.
Onconova Therapeutics (ONTX)
Onconova Therapeutics (NASDAQ: ONTX) is a phase III stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials are aimed at unmet medical needs of patients with myelodysplastic syndromes (MDS). For more information, visit the company's website at www.onconova.com.
Quest Resource Holding (QRHC)
Quest Resource Holding (NASDAQ: QRHC) provides management programs to reuse, recycle and dispose various waste streams and recyclables in the United States. The company offers recycling management services for motor oil, oil filters, scrap tires, grease and cooking oil, and expired food products; and various other materials, such as glass, cardboards, paper, metals, plastic oil bottles, hazardous materials, HDPE plastics, construction debris, batteries, mercury, lights, regulated medical waste, electronics, parts cleaners, used absorbents, solid waste, and industrial cleaning products. It also provides landfill diversion services and environmental certification services. For more information, visit the company's website at www.qrhc.com.
Americas Silver (USAPF)
Americas Silver (OTC: USAPF) is a Canadian-based junior silver producer with assets in the Americas and a strong operating platform. Annual production for 2016 is expected to be 5.0 million-5.6 million silver equivalent ounces. The company has two established producing mines, a third mine in construction, and an advanced stage exploration project. Construction has commenced on the San Rafael project located in Mexico that will increase the company's silver equivalent production to 7.0 million-7.5 million ounces between $7 and $8 silver all in sustaining costs in 2018. For more information, visit the company's website at www.americassilvercorp.com.
BioSpecifics Technologies (BSTC)
BioSpecifics Technologies (NASDAQ: BSTC) is a biopharmaceutical company that engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. BioSpecifics is also involved in the development of other clinical indications for which collagenase injection has been tested. For more information, visit the company's website at www.biospecifics.com.
NovoCure (NASDAQ: NVCR) is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields (TTFields) for the treatment of solid tumor cancers. The company's commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. Headquartered in Jersey, Novocure has operations in Portsmouth, New Hampshire; Malvern, Pennsylvania; and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For more information, visit the company's website at www.novocure.com.
Torchlight Energy (TRCH)
Torchlight Energy (NASDAQ: TRCH) engages in the acquisition, exploration, exploitation, and/or development of oil and natural gas properties in the United States. It has interests in four oil and gas projects, including the Marcelina Creek Field Development in Wilson County, Texas; the Ring Energy Joint Venture in Southwest Kansas; the Hunton play in Central Oklahoma; and the Orogrande project in Hudspeth County, Texas. It also had interest in a commercial salt water disposal facility in Seminole, Oklahoma. For more information, visit the company's website torchlightenergy.com.
Aytu BioScience (AYTU)
Aytu BioScience (OTC: AYTU) is a specialty healthcare company that focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer; and Primsol, an oral solution for urinary tract infections. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. For more information, visit the company's website at www.aytubio.com.
BioTime (NYSE: BTX) is engaged in developing and commercializing novel therapies based on HyStem cell delivery and pluripotent stem cell technology platforms. The company focuses on regenerative medicine and is developing Renevia, currently in pivotal clinical trial for HIV related facial lipoatrophy; AST-VAC1, a cancer immunotherapy in phase II clinical trials for the treatment of acute myeloid leukemia; OpRegen, in phase I/IIa clinical trial to treat the dry form of age-related macular degeneration; and AST-OPC1, in phase I/II clinical trials for spinal cord injuries. The company also develops Premvia for wound management. For more information, visit the company's website at www.biotimeinc.com.
Comtech Telecommunications (CMTL)
Comtech Telecommunications (NASDAQ: CMTL) designs, develops, produces and markets products, systems and services for communications solutions. The company's Commercial Solutions segment provides ground-based equipment; traveling wave tube amplifiers comprising high power narrow-band amplifiers that are used to amplify signals from satellite earth stations; and safety and security technology solutions that enable 911 call routing. This segment also offers enterprise application technologies, including location-based technology, such as Trusted Location, a software-based scoring system that allows providers to determine mobile location and identify fraudulent behavior and other security risks; and Look4, an application that enables customers to build their own applications. For more information, visit the company's website at www.comtechtel.com.
Arch Therapeutics (ARTH)
Arch Therapeutics (OTC: ARTH) operates as a life science medical device company. Arch develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. The company's primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. For more information, visit the company's website at www.archtherapeutics.com.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is engaged in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate currently being evaluated in a phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. For more information, visit the company's website at www.cellectar.com.